Cargando…
Response to Letter; Discrimination between Benign and Malignant Post-SARS-CoV-2 Vaccination Lymphadenopathy is Feasible, to Our Article; Axillary Adenopathy in Patients with Recent COVID-19 Vaccination: A New Diagnostic Dilemma
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Korean Society of Radiology
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9240295/ https://www.ncbi.nlm.nih.gov/pubmed/35695318 http://dx.doi.org/10.3348/kjr.2022.0207 |
_version_ | 1784737507584245760 |
---|---|
author | Ashoor, Arwa Shephard, Julie Lissidini, Germana Nicosia, Luca |
author_facet | Ashoor, Arwa Shephard, Julie Lissidini, Germana Nicosia, Luca |
author_sort | Ashoor, Arwa |
collection | PubMed |
description | |
format | Online Article Text |
id | pubmed-9240295 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | The Korean Society of Radiology |
record_format | MEDLINE/PubMed |
spelling | pubmed-92402952022-07-07 Response to Letter; Discrimination between Benign and Malignant Post-SARS-CoV-2 Vaccination Lymphadenopathy is Feasible, to Our Article; Axillary Adenopathy in Patients with Recent COVID-19 Vaccination: A New Diagnostic Dilemma Ashoor, Arwa Shephard, Julie Lissidini, Germana Nicosia, Luca Korean J Radiol Letter to the Editor The Korean Society of Radiology 2022-07 2022-05-31 /pmc/articles/PMC9240295/ /pubmed/35695318 http://dx.doi.org/10.3348/kjr.2022.0207 Text en Copyright © 2022 The Korean Society of Radiology https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0 (https://creativecommons.org/licenses/by-nc/4.0/) ) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Letter to the Editor Ashoor, Arwa Shephard, Julie Lissidini, Germana Nicosia, Luca Response to Letter; Discrimination between Benign and Malignant Post-SARS-CoV-2 Vaccination Lymphadenopathy is Feasible, to Our Article; Axillary Adenopathy in Patients with Recent COVID-19 Vaccination: A New Diagnostic Dilemma |
title | Response to Letter; Discrimination between Benign and Malignant Post-SARS-CoV-2 Vaccination Lymphadenopathy is Feasible, to Our Article; Axillary Adenopathy in Patients with Recent COVID-19 Vaccination: A New Diagnostic Dilemma |
title_full | Response to Letter; Discrimination between Benign and Malignant Post-SARS-CoV-2 Vaccination Lymphadenopathy is Feasible, to Our Article; Axillary Adenopathy in Patients with Recent COVID-19 Vaccination: A New Diagnostic Dilemma |
title_fullStr | Response to Letter; Discrimination between Benign and Malignant Post-SARS-CoV-2 Vaccination Lymphadenopathy is Feasible, to Our Article; Axillary Adenopathy in Patients with Recent COVID-19 Vaccination: A New Diagnostic Dilemma |
title_full_unstemmed | Response to Letter; Discrimination between Benign and Malignant Post-SARS-CoV-2 Vaccination Lymphadenopathy is Feasible, to Our Article; Axillary Adenopathy in Patients with Recent COVID-19 Vaccination: A New Diagnostic Dilemma |
title_short | Response to Letter; Discrimination between Benign and Malignant Post-SARS-CoV-2 Vaccination Lymphadenopathy is Feasible, to Our Article; Axillary Adenopathy in Patients with Recent COVID-19 Vaccination: A New Diagnostic Dilemma |
title_sort | response to letter; discrimination between benign and malignant post-sars-cov-2 vaccination lymphadenopathy is feasible, to our article; axillary adenopathy in patients with recent covid-19 vaccination: a new diagnostic dilemma |
topic | Letter to the Editor |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9240295/ https://www.ncbi.nlm.nih.gov/pubmed/35695318 http://dx.doi.org/10.3348/kjr.2022.0207 |
work_keys_str_mv | AT ashoorarwa responsetoletterdiscriminationbetweenbenignandmalignantpostsarscov2vaccinationlymphadenopathyisfeasibletoourarticleaxillaryadenopathyinpatientswithrecentcovid19vaccinationanewdiagnosticdilemma AT shephardjulie responsetoletterdiscriminationbetweenbenignandmalignantpostsarscov2vaccinationlymphadenopathyisfeasibletoourarticleaxillaryadenopathyinpatientswithrecentcovid19vaccinationanewdiagnosticdilemma AT lissidinigermana responsetoletterdiscriminationbetweenbenignandmalignantpostsarscov2vaccinationlymphadenopathyisfeasibletoourarticleaxillaryadenopathyinpatientswithrecentcovid19vaccinationanewdiagnosticdilemma AT nicosialuca responsetoletterdiscriminationbetweenbenignandmalignantpostsarscov2vaccinationlymphadenopathyisfeasibletoourarticleaxillaryadenopathyinpatientswithrecentcovid19vaccinationanewdiagnosticdilemma |